

# Global Systemic Sclerosis Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/GB7A656D03A1EN.html>

Date: July 2024

Pages: 128

Price: US\$ 3,480.00 (Single User License)

ID: GB7A656D03A1EN

## Abstracts

According to our (Global Info Research) latest study, the global Systemic Sclerosis Drug market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Systemic Sclerosis Drug industry chain, the market status of Hospital (ARG-201, Belimumab), Clinic (ARG-201, Belimumab), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Systemic Sclerosis Drug.

Regionally, the report analyzes the Systemic Sclerosis Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Systemic Sclerosis Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.

#### Key Features:

The report presents comprehensive understanding of the Systemic Sclerosis Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Systemic Sclerosis Drug industry.

The report involves analyzing the market at a macro level:

**Market Sizing and Segmentation:** Report collect data on the overall market size, including the sales quantity (K Pcs), revenue generated, and market share of different by Type (e.g., ARG-201, Belimumab).

**Industry Analysis:** Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Systemic Sclerosis Drug market.

**Regional Analysis:** The report involves examining the Systemic Sclerosis Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

**Market Projections:** Report covers the gathered data and analysis to make future projections and forecasts for the Systemic Sclerosis Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Systemic Sclerosis Drug:

**Company Analysis:** Report covers individual Systemic Sclerosis Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their

financial performance, market positioning, product portfolios, partnerships, and strategies.

**Consumer Analysis:** Report covers data on consumer behaviour, preferences, and attitudes towards Systemic Sclerosis Drug. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).

**Technology Analysis:** Report covers specific technologies relevant to Systemic Sclerosis Drug. It assesses the current state, advancements, and potential future developments in Systemic Sclerosis Drug areas.

**Competitive Landscape:** By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Systemic Sclerosis Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

**Market Validation:** The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

## Market Segmentation

Systemic Sclerosis Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

## Market segment by Type

ARG-201

Belimumab

BL-1110

BOT-191

C-82

Others

## Market segment by Application

Hospital

Clinic

ASCs

Others

## Major players covered

Allergan Plc

Angion Biomedica Corp.

arGentis Pharmaceuticals, LLC

Bayer AG

BioLineRx, Ltd.

BiOrion Technologies B.V.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Corbus pharmaceuticals, Inc.

CSL Limited

Daval International Limited

Digna Biotech, S.L.

F. Hoffmann-La Roche Ltd.

Fibrocell Science, Inc.

GenKyoTex S.A.

GlaxoSmithKline Plc

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Systemic Sclerosis Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Systemic Sclerosis Drug, with price, sales, revenue and global market share of Systemic Sclerosis Drug from 2019 to 2024.

Chapter 3, the Systemic Sclerosis Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Systemic Sclerosis Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023. and Systemic Sclerosis Drug market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Systemic Sclerosis Drug.

Chapter 14 and 15, to describe Systemic Sclerosis Drug sales channel, distributors, customers, research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope of Systemic Sclerosis Drug

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Systemic Sclerosis Drug Consumption Value by Type: 2019 Versus 2023 Versus 2030

1.3.2 ARG-201

1.3.3 Belimumab

1.3.4 BL-1110

1.3.5 BOT-191

1.3.6 C-82

1.3.7 Others

1.4 Market Analysis by Application

1.4.1 Overview: Global Systemic Sclerosis Drug Consumption Value by Application: 2019 Versus 2023 Versus 2030

1.4.2 Hospital

1.4.3 Clinic

1.4.4 ASCs

1.4.5 Others

1.5 Global Systemic Sclerosis Drug Market Size & Forecast

1.5.1 Global Systemic Sclerosis Drug Consumption Value (2019 & 2023 & 2030)

1.5.2 Global Systemic Sclerosis Drug Sales Quantity (2019-2030)

1.5.3 Global Systemic Sclerosis Drug Average Price (2019-2030)

### 2 MANUFACTURERS PROFILES

2.1 Allergan Plc

2.1.1 Allergan Plc Details

2.1.2 Allergan Plc Major Business

2.1.3 Allergan Plc Systemic Sclerosis Drug Product and Services

2.1.4 Allergan Plc Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.1.5 Allergan Plc Recent Developments/Updates

2.2 Angion Biomedica Corp.

2.2.1 Angion Biomedica Corp. Details

2.2.2 Angion Biomedica Corp. Major Business

- 2.2.3 Angion Biomedica Corp. Systemic Sclerosis Drug Product and Services
- 2.2.4 Angion Biomedica Corp. Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Angion Biomedica Corp. Recent Developments/Updates
- 2.3 arGentis Pharmaceuticals, LLC
  - 2.3.1 arGentis Pharmaceuticals, LLC Details
  - 2.3.2 arGentis Pharmaceuticals, LLC Major Business
  - 2.3.3 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product and Services
  - 2.3.4 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  - 2.3.5 arGentis Pharmaceuticals, LLC Recent Developments/Updates
- 2.4 Bayer AG
  - 2.4.1 Bayer AG Details
  - 2.4.2 Bayer AG Major Business
  - 2.4.3 Bayer AG Systemic Sclerosis Drug Product and Services
  - 2.4.4 Bayer AG Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  - 2.4.5 Bayer AG Recent Developments/Updates
- 2.5 BioLineRx, Ltd.
  - 2.5.1 BioLineRx, Ltd. Details
  - 2.5.2 BioLineRx, Ltd. Major Business
  - 2.5.3 BioLineRx, Ltd. Systemic Sclerosis Drug Product and Services
  - 2.5.4 BioLineRx, Ltd. Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  - 2.5.5 BioLineRx, Ltd. Recent Developments/Updates
- 2.6 BiOrion Technologies B.V.
  - 2.6.1 BiOrion Technologies B.V. Details
  - 2.6.2 BiOrion Technologies B.V. Major Business
  - 2.6.3 BiOrion Technologies B.V. Systemic Sclerosis Drug Product and Services
  - 2.6.4 BiOrion Technologies B.V. Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  - 2.6.5 BiOrion Technologies B.V. Recent Developments/Updates
- 2.7 Boehringer Ingelheim GmbH
  - 2.7.1 Boehringer Ingelheim GmbH Details
  - 2.7.2 Boehringer Ingelheim GmbH Major Business
  - 2.7.3 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product and Services
  - 2.7.4 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  - 2.7.5 Boehringer Ingelheim GmbH Recent Developments/Updates



## 2.8 Bristol-Myers Squibb Company

### 2.8.1 Bristol-Myers Squibb Company Details

### 2.8.2 Bristol-Myers Squibb Company Major Business

### 2.8.3 Bristol-Myers Squibb Company Systemic Sclerosis Drug Product and Services

### 2.8.4 Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

### 2.8.5 Bristol-Myers Squibb Company Recent Developments/Updates

## 2.9 Corbus pharmaceuticals, Inc.

### 2.9.1 Corbus pharmaceuticals, Inc. Details

### 2.9.2 Corbus pharmaceuticals, Inc. Major Business

### 2.9.3 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product and Services

### 2.9.4 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

### 2.9.5 Corbus pharmaceuticals, Inc. Recent Developments/Updates

## 2.10 CSL Limited

### 2.10.1 CSL Limited Details

### 2.10.2 CSL Limited Major Business

### 2.10.3 CSL Limited Systemic Sclerosis Drug Product and Services

### 2.10.4 CSL Limited Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

### 2.10.5 CSL Limited Recent Developments/Updates

## 2.11 Daval International Limited

### 2.11.1 Daval International Limited Details

### 2.11.2 Daval International Limited Major Business

### 2.11.3 Daval International Limited Systemic Sclerosis Drug Product and Services

### 2.11.4 Daval International Limited Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

### 2.11.5 Daval International Limited Recent Developments/Updates

## 2.12 Digna Biotech, S.L.

### 2.12.1 Digna Biotech, S.L. Details

### 2.12.2 Digna Biotech, S.L. Major Business

### 2.12.3 Digna Biotech, S.L. Systemic Sclerosis Drug Product and Services

### 2.12.4 Digna Biotech, S.L. Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

### 2.12.5 Digna Biotech, S.L. Recent Developments/Updates

## 2.13 F. Hoffmann-La Roche Ltd.

### 2.13.1 F. Hoffmann-La Roche Ltd. Details

### 2.13.2 F. Hoffmann-La Roche Ltd. Major Business

### 2.13.3 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product and Services

2.13.4 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.13.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates

2.14 Fibrocell Science, Inc.

2.14.1 Fibrocell Science, Inc. Details

2.14.2 Fibrocell Science, Inc. Major Business

2.14.3 Fibrocell Science, Inc. Systemic Sclerosis Drug Product and Services

2.14.4 Fibrocell Science, Inc. Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.14.5 Fibrocell Science, Inc. Recent Developments/Updates

2.15 GenKyoTex S.A.

2.15.1 GenKyoTex S.A. Details

2.15.2 GenKyoTex S.A. Major Business

2.15.3 GenKyoTex S.A. Systemic Sclerosis Drug Product and Services

2.15.4 GenKyoTex S.A. Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.15.5 GenKyoTex S.A. Recent Developments/Updates

2.16 GlaxoSmithKline Plc

2.16.1 GlaxoSmithKline Plc Details

2.16.2 GlaxoSmithKline Plc Major Business

2.16.3 GlaxoSmithKline Plc Systemic Sclerosis Drug Product and Services

2.16.4 GlaxoSmithKline Plc Systemic Sclerosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.16.5 GlaxoSmithKline Plc Recent Developments/Updates

### **3 COMPETITIVE ENVIRONMENT: SYSTEMIC SCLEROSIS DRUG BY MANUFACTURER**

3.1 Global Systemic Sclerosis Drug Sales Quantity by Manufacturer (2019-2024)

3.2 Global Systemic Sclerosis Drug Revenue by Manufacturer (2019-2024)

3.3 Global Systemic Sclerosis Drug Average Price by Manufacturer (2019-2024)

3.4 Market Share Analysis (2023)

3.4.1 Producer Shipments of Systemic Sclerosis Drug by Manufacturer Revenue (\$MM) and Market Share (%): 2023

3.4.2 Top 3 Systemic Sclerosis Drug Manufacturer Market Share in 2023

3.4.2 Top 6 Systemic Sclerosis Drug Manufacturer Market Share in 2023

3.5 Systemic Sclerosis Drug Market: Overall Company Footprint Analysis

3.5.1 Systemic Sclerosis Drug Market: Region Footprint

3.5.2 Systemic Sclerosis Drug Market: Company Product Type Footprint

- 3.5.3 Systemic Sclerosis Drug Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

## **4 CONSUMPTION ANALYSIS BY REGION**

- 4.1 Global Systemic Sclerosis Drug Market Size by Region
  - 4.1.1 Global Systemic Sclerosis Drug Sales Quantity by Region (2019-2030)
  - 4.1.2 Global Systemic Sclerosis Drug Consumption Value by Region (2019-2030)
  - 4.1.3 Global Systemic Sclerosis Drug Average Price by Region (2019-2030)
- 4.2 North America Systemic Sclerosis Drug Consumption Value (2019-2030)
- 4.3 Europe Systemic Sclerosis Drug Consumption Value (2019-2030)
- 4.4 Asia-Pacific Systemic Sclerosis Drug Consumption Value (2019-2030)
- 4.5 South America Systemic Sclerosis Drug Consumption Value (2019-2030)
- 4.6 Middle East and Africa Systemic Sclerosis Drug Consumption Value (2019-2030)

## **5 MARKET SEGMENT BY TYPE**

- 5.1 Global Systemic Sclerosis Drug Sales Quantity by Type (2019-2030)
- 5.2 Global Systemic Sclerosis Drug Consumption Value by Type (2019-2030)
- 5.3 Global Systemic Sclerosis Drug Average Price by Type (2019-2030)

## **6 MARKET SEGMENT BY APPLICATION**

- 6.1 Global Systemic Sclerosis Drug Sales Quantity by Application (2019-2030)
- 6.2 Global Systemic Sclerosis Drug Consumption Value by Application (2019-2030)
- 6.3 Global Systemic Sclerosis Drug Average Price by Application (2019-2030)

## **7 NORTH AMERICA**

- 7.1 North America Systemic Sclerosis Drug Sales Quantity by Type (2019-2030)
- 7.2 North America Systemic Sclerosis Drug Sales Quantity by Application (2019-2030)
- 7.3 North America Systemic Sclerosis Drug Market Size by Country
  - 7.3.1 North America Systemic Sclerosis Drug Sales Quantity by Country (2019-2030)
  - 7.3.2 North America Systemic Sclerosis Drug Consumption Value by Country (2019-2030)
  - 7.3.3 United States Market Size and Forecast (2019-2030)
  - 7.3.4 Canada Market Size and Forecast (2019-2030)
  - 7.3.5 Mexico Market Size and Forecast (2019-2030)

## **8 EUROPE**

- 8.1 Europe Systemic Sclerosis Drug Sales Quantity by Type (2019-2030)
- 8.2 Europe Systemic Sclerosis Drug Sales Quantity by Application (2019-2030)
- 8.3 Europe Systemic Sclerosis Drug Market Size by Country
  - 8.3.1 Europe Systemic Sclerosis Drug Sales Quantity by Country (2019-2030)
  - 8.3.2 Europe Systemic Sclerosis Drug Consumption Value by Country (2019-2030)
  - 8.3.3 Germany Market Size and Forecast (2019-2030)
  - 8.3.4 France Market Size and Forecast (2019-2030)
  - 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
  - 8.3.6 Russia Market Size and Forecast (2019-2030)
  - 8.3.7 Italy Market Size and Forecast (2019-2030)

## **9 ASIA-PACIFIC**

- 9.1 Asia-Pacific Systemic Sclerosis Drug Sales Quantity by Type (2019-2030)
- 9.2 Asia-Pacific Systemic Sclerosis Drug Sales Quantity by Application (2019-2030)
- 9.3 Asia-Pacific Systemic Sclerosis Drug Market Size by Region
  - 9.3.1 Asia-Pacific Systemic Sclerosis Drug Sales Quantity by Region (2019-2030)
  - 9.3.2 Asia-Pacific Systemic Sclerosis Drug Consumption Value by Region (2019-2030)
  - 9.3.3 China Market Size and Forecast (2019-2030)
  - 9.3.4 Japan Market Size and Forecast (2019-2030)
  - 9.3.5 Korea Market Size and Forecast (2019-2030)
  - 9.3.6 India Market Size and Forecast (2019-2030)
  - 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
  - 9.3.8 Australia Market Size and Forecast (2019-2030)

## **10 SOUTH AMERICA**

- 10.1 South America Systemic Sclerosis Drug Sales Quantity by Type (2019-2030)
- 10.2 South America Systemic Sclerosis Drug Sales Quantity by Application (2019-2030)
- 10.3 South America Systemic Sclerosis Drug Market Size by Country
  - 10.3.1 South America Systemic Sclerosis Drug Sales Quantity by Country (2019-2030)
  - 10.3.2 South America Systemic Sclerosis Drug Consumption Value by Country (2019-2030)
  - 10.3.3 Brazil Market Size and Forecast (2019-2030)
  - 10.3.4 Argentina Market Size and Forecast (2019-2030)

## **11 MIDDLE EAST & AFRICA**

11.1 Middle East & Africa Systemic Sclerosis Drug Sales Quantity by Type (2019-2030)

11.2 Middle East & Africa Systemic Sclerosis Drug Sales Quantity by Application (2019-2030)

11.3 Middle East & Africa Systemic Sclerosis Drug Market Size by Country

11.3.1 Middle East & Africa Systemic Sclerosis Drug Sales Quantity by Country (2019-2030)

11.3.2 Middle East & Africa Systemic Sclerosis Drug Consumption Value by Country (2019-2030)

11.3.3 Turkey Market Size and Forecast (2019-2030)

11.3.4 Egypt Market Size and Forecast (2019-2030)

11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)

11.3.6 South Africa Market Size and Forecast (2019-2030)

## **12 MARKET DYNAMICS**

12.1 Systemic Sclerosis Drug Market Drivers

12.2 Systemic Sclerosis Drug Market Restraints

12.3 Systemic Sclerosis Drug Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

## **13 RAW MATERIAL AND INDUSTRY CHAIN**

13.1 Raw Material of Systemic Sclerosis Drug and Key Manufacturers

13.2 Manufacturing Costs Percentage of Systemic Sclerosis Drug

13.3 Systemic Sclerosis Drug Production Process

13.4 Systemic Sclerosis Drug Industrial Chain

## **14 SHIPMENTS BY DISTRIBUTION CHANNEL**

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Systemic Sclerosis Drug Typical Distributors

14.3 Systemic Sclerosis Drug Typical Customers

## **15 RESEARCH FINDINGS AND CONCLUSION**

## **16 APPENDIX**

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Systemic Sclerosis Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Table 2. Global Systemic Sclerosis Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Table 3. Allergan Plc Basic Information, Manufacturing Base and Competitors

Table 4. Allergan Plc Major Business

Table 5. Allergan Plc Systemic Sclerosis Drug Product and Services

Table 6. Allergan Plc Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 7. Allergan Plc Recent Developments/Updates

Table 8. Angion Biomedica Corp. Basic Information, Manufacturing Base and Competitors

Table 9. Angion Biomedica Corp. Major Business

Table 10. Angion Biomedica Corp. Systemic Sclerosis Drug Product and Services

Table 11. Angion Biomedica Corp. Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 12. Angion Biomedica Corp. Recent Developments/Updates

Table 13. arGentis Pharmaceuticals, LLC Basic Information, Manufacturing Base and Competitors

Table 14. arGentis Pharmaceuticals, LLC Major Business

Table 15. arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product and Services

Table 16. arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 17. arGentis Pharmaceuticals, LLC Recent Developments/Updates

Table 18. Bayer AG Basic Information, Manufacturing Base and Competitors

Table 19. Bayer AG Major Business

Table 20. Bayer AG Systemic Sclerosis Drug Product and Services

Table 21. Bayer AG Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 22. Bayer AG Recent Developments/Updates

Table 23. BioLineRx, Ltd. Basic Information, Manufacturing Base and Competitors

Table 24. BioLineRx, Ltd. Major Business

- Table 25. BioLineRx, Ltd. Systemic Sclerosis Drug Product and Services
- Table 26. BioLineRx, Ltd. Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 27. BioLineRx, Ltd. Recent Developments/Updates
- Table 28. BiOrion Technologies B.V. Basic Information, Manufacturing Base and Competitors
- Table 29. BiOrion Technologies B.V. Major Business
- Table 30. BiOrion Technologies B.V. Systemic Sclerosis Drug Product and Services
- Table 31. BiOrion Technologies B.V. Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 32. BiOrion Technologies B.V. Recent Developments/Updates
- Table 33. Boehringer Ingelheim GmbH Basic Information, Manufacturing Base and Competitors
- Table 34. Boehringer Ingelheim GmbH Major Business
- Table 35. Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product and Services
- Table 36. Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 37. Boehringer Ingelheim GmbH Recent Developments/Updates
- Table 38. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
- Table 39. Bristol-Myers Squibb Company Major Business
- Table 40. Bristol-Myers Squibb Company Systemic Sclerosis Drug Product and Services
- Table 41. Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 42. Bristol-Myers Squibb Company Recent Developments/Updates
- Table 43. Corbus pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
- Table 44. Corbus pharmaceuticals, Inc. Major Business
- Table 45. Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product and Services
- Table 46. Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 47. Corbus pharmaceuticals, Inc. Recent Developments/Updates
- Table 48. CSL Limited Basic Information, Manufacturing Base and Competitors
- Table 49. CSL Limited Major Business



- Table 50. CSL Limited Systemic Sclerosis Drug Product and Services
- Table 51. CSL Limited Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 52. CSL Limited Recent Developments/Updates
- Table 53. Daval International Limited Basic Information, Manufacturing Base and Competitors
- Table 54. Daval International Limited Major Business
- Table 55. Daval International Limited Systemic Sclerosis Drug Product and Services
- Table 56. Daval International Limited Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 57. Daval International Limited Recent Developments/Updates
- Table 58. Digna Biotech, S.L. Basic Information, Manufacturing Base and Competitors
- Table 59. Digna Biotech, S.L. Major Business
- Table 60. Digna Biotech, S.L. Systemic Sclerosis Drug Product and Services
- Table 61. Digna Biotech, S.L. Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 62. Digna Biotech, S.L. Recent Developments/Updates
- Table 63. F. Hoffmann-La Roche Ltd. Basic Information, Manufacturing Base and Competitors
- Table 64. F. Hoffmann-La Roche Ltd. Major Business
- Table 65. F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product and Services
- Table 66. F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 67. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
- Table 68. Fibrocell Science, Inc. Basic Information, Manufacturing Base and Competitors
- Table 69. Fibrocell Science, Inc. Major Business
- Table 70. Fibrocell Science, Inc. Systemic Sclerosis Drug Product and Services
- Table 71. Fibrocell Science, Inc. Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 72. Fibrocell Science, Inc. Recent Developments/Updates
- Table 73. GenKyoTex S.A. Basic Information, Manufacturing Base and Competitors
- Table 74. GenKyoTex S.A. Major Business
- Table 75. GenKyoTex S.A. Systemic Sclerosis Drug Product and Services
- Table 76. GenKyoTex S.A. Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

- Table 77. GenKyoTex S.A. Recent Developments/Updates
- Table 78. GlaxoSmithKline Plc Basic Information, Manufacturing Base and Competitors
- Table 79. GlaxoSmithKline Plc Major Business
- Table 80. GlaxoSmithKline Plc Systemic Sclerosis Drug Product and Services
- Table 81. GlaxoSmithKline Plc Systemic Sclerosis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 82. GlaxoSmithKline Plc Recent Developments/Updates
- Table 83. Global Systemic Sclerosis Drug Sales Quantity by Manufacturer (2019-2024) & (K Pcs)
- Table 84. Global Systemic Sclerosis Drug Revenue by Manufacturer (2019-2024) & (USD Million)
- Table 85. Global Systemic Sclerosis Drug Average Price by Manufacturer (2019-2024) & (USD/Pcs)
- Table 86. Market Position of Manufacturers in Systemic Sclerosis Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
- Table 87. Head Office and Systemic Sclerosis Drug Production Site of Key Manufacturer
- Table 88. Systemic Sclerosis Drug Market: Company Product Type Footprint
- Table 89. Systemic Sclerosis Drug Market: Company Product Application Footprint
- Table 90. Systemic Sclerosis Drug New Market Entrants and Barriers to Market Entry
- Table 91. Systemic Sclerosis Drug Mergers, Acquisition, Agreements, and Collaborations
- Table 92. Global Systemic Sclerosis Drug Sales Quantity by Region (2019-2024) & (K Pcs)
- Table 93. Global Systemic Sclerosis Drug Sales Quantity by Region (2025-2030) & (K Pcs)
- Table 94. Global Systemic Sclerosis Drug Consumption Value by Region (2019-2024) & (USD Million)
- Table 95. Global Systemic Sclerosis Drug Consumption Value by Region (2025-2030) & (USD Million)
- Table 96. Global Systemic Sclerosis Drug Average Price by Region (2019-2024) & (USD/Pcs)
- Table 97. Global Systemic Sclerosis Drug Average Price by Region (2025-2030) & (USD/Pcs)
- Table 98. Global Systemic Sclerosis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
- Table 99. Global Systemic Sclerosis Drug Sales Quantity by Type (2025-2030) & (K Pcs)

- Table 100. Global Systemic Sclerosis Drug Consumption Value by Type (2019-2024) & (USD Million)
- Table 101. Global Systemic Sclerosis Drug Consumption Value by Type (2025-2030) & (USD Million)
- Table 102. Global Systemic Sclerosis Drug Average Price by Type (2019-2024) & (USD/Pcs)
- Table 103. Global Systemic Sclerosis Drug Average Price by Type (2025-2030) & (USD/Pcs)
- Table 104. Global Systemic Sclerosis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
- Table 105. Global Systemic Sclerosis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
- Table 106. Global Systemic Sclerosis Drug Consumption Value by Application (2019-2024) & (USD Million)
- Table 107. Global Systemic Sclerosis Drug Consumption Value by Application (2025-2030) & (USD Million)
- Table 108. Global Systemic Sclerosis Drug Average Price by Application (2019-2024) & (USD/Pcs)
- Table 109. Global Systemic Sclerosis Drug Average Price by Application (2025-2030) & (USD/Pcs)
- Table 110. North America Systemic Sclerosis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
- Table 111. North America Systemic Sclerosis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
- Table 112. North America Systemic Sclerosis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
- Table 113. North America Systemic Sclerosis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
- Table 114. North America Systemic Sclerosis Drug Sales Quantity by Country (2019-2024) & (K Pcs)
- Table 115. North America Systemic Sclerosis Drug Sales Quantity by Country (2025-2030) & (K Pcs)
- Table 116. North America Systemic Sclerosis Drug Consumption Value by Country (2019-2024) & (USD Million)
- Table 117. North America Systemic Sclerosis Drug Consumption Value by Country (2025-2030) & (USD Million)
- Table 118. Europe Systemic Sclerosis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
- Table 119. Europe Systemic Sclerosis Drug Sales Quantity by Type (2025-2030) & (K

Pcs)

Table 120. Europe Systemic Sclerosis Drug Sales Quantity by Application (2019-2024) & (K Pcs)

Table 121. Europe Systemic Sclerosis Drug Sales Quantity by Application (2025-2030) & (K Pcs)

Table 122. Europe Systemic Sclerosis Drug Sales Quantity by Country (2019-2024) & (K Pcs)

Table 123. Europe Systemic Sclerosis Drug Sales Quantity by Country (2025-2030) & (K Pcs)

Table 124. Europe Systemic Sclerosis Drug Consumption Value by Country (2019-2024) & (USD Million)

Table 125. Europe Systemic Sclerosis Drug Consumption Value by Country (2025-2030) & (USD Million)

Table 126. Asia-Pacific Systemic Sclerosis Drug Sales Quantity by Type (2019-2024) & (K Pcs)

Table 127. Asia-Pacific Systemic Sclerosis Drug Sales Quantity by Type (2025-2030) & (K Pcs)

Table 128. Asia-Pacific Systemic Sclerosis Drug Sales Quantity by Application (2019-2024) & (K Pcs)

Table 129. Asia-Pacific Systemic Sclerosis Drug Sales Quantity by Application (2025-2030) & (K Pcs)

Table 130. Asia-Pacific Systemic Sclerosis Drug Sales Quantity by Region (2019-2024) & (K Pcs)

Table 131. Asia-Pacific Systemic Sclerosis Drug Sales Quantity by Region (2025-2030) & (K Pcs)

Table 132. Asia-Pacific Systemic Sclerosis Drug Consumption Value by Region (2019-2024) & (USD Million)

Table 133. Asia-Pacific Systemic Sclerosis Drug Consumption Value by Region (2025-2030) & (USD Million)

Table 134. South America Systemic Sclerosis Drug Sales Quantity by Type (2019-2024) & (K Pcs)

Table 135. South America Systemic Sclerosis Drug Sales Quantity by Type (2025-2030) & (K Pcs)

Table 136. South America Systemic Sclerosis Drug Sales Quantity by Application (2019-2024) & (K Pcs)

Table 137. South America Systemic Sclerosis Drug Sales Quantity by Application (2025-2030) & (K Pcs)

Table 138. South America Systemic Sclerosis Drug Sales Quantity by Country (2019-2024) & (K Pcs)

Table 139. South America Systemic Sclerosis Drug Sales Quantity by Country (2025-2030) & (K Pcs)

Table 140. South America Systemic Sclerosis Drug Consumption Value by Country (2019-2024) & (USD Million)

Table 141. South America Systemic Sclerosis Drug Consumption Value by Country (2025-2030) & (USD Million)

Table 142. Middle East & Africa Systemic Sclerosis Drug Sales Quantity by Type (2019-2024) & (K Pcs)

Table 143. Middle East & Africa Systemic Sclerosis Drug Sales Quantity by Type (2025-2030) & (K Pcs)

Table 144. Middle East & Africa Systemic Sclerosis Drug Sales Quantity by Application (2019-2024) & (K Pcs)

Table 145. Middle East & Africa Systemic Sclerosis Drug Sales Quantity by Application (2025-2030) & (K Pcs)

Table 146. Middle East & Africa Systemic Sclerosis Drug Sales Quantity by Region (2019-2024) & (K Pcs)

Table 147. Middle East & Africa Systemic Sclerosis Drug Sales Quantity by Region (2025-2030) & (K Pcs)

Table 148. Middle East & Africa Systemic Sclerosis Drug Consumption Value by Region (2019-2024) & (USD Million)

Table 149. Middle East & Africa Systemic Sclerosis Drug Consumption Value by Region (2025-2030) & (USD Million)

Table 150. Systemic Sclerosis Drug Raw Material

Table 151. Key Manufacturers of Systemic Sclerosis Drug Raw Materials

Table 152. Systemic Sclerosis Drug Typical Distributors

Table 153. Systemic Sclerosis Drug Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. Systemic Sclerosis Drug Picture

Figure 2. Global Systemic Sclerosis Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Figure 3. Global Systemic Sclerosis Drug Consumption Value Market Share by Type in 2023

Figure 4. ARG-201 Examples

Figure 5. Belimumab Examples

Figure 6. BL-1110 Examples

Figure 7. BOT-191 Examples

Figure 8. C-82 Examples

Figure 9. Others Examples

Figure 10. Global Systemic Sclerosis Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Figure 11. Global Systemic Sclerosis Drug Consumption Value Market Share by Application in 2023

Figure 12. Hospital Examples

Figure 13. Clinic Examples

Figure 14. ASCs Examples

Figure 15. Others Examples

Figure 16. Global Systemic Sclerosis Drug Consumption Value, (USD Million): 2019 & 2023 & 2030

Figure 17. Global Systemic Sclerosis Drug Consumption Value and Forecast (2019-2030) & (USD Million)

Figure 18. Global Systemic Sclerosis Drug Sales Quantity (2019-2030) & (K Pcs)

Figure 19. Global Systemic Sclerosis Drug Average Price (2019-2030) & (USD/Pcs)

Figure 20. Global Systemic Sclerosis Drug Sales Quantity Market Share by Manufacturer in 2023

Figure 21. Global Systemic Sclerosis Drug Consumption Value Market Share by Manufacturer in 2023

Figure 22. Producer Shipments of Systemic Sclerosis Drug by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2023

Figure 23. Top 3 Systemic Sclerosis Drug Manufacturer (Consumption Value) Market Share in 2023

Figure 24. Top 6 Systemic Sclerosis Drug Manufacturer (Consumption Value) Market Share in 2023

Figure 25. Global Systemic Sclerosis Drug Sales Quantity Market Share by Region (2019-2030)

Figure 26. Global Systemic Sclerosis Drug Consumption Value Market Share by Region (2019-2030)

Figure 27. North America Systemic Sclerosis Drug Consumption Value (2019-2030) & (USD Million)

Figure 28. Europe Systemic Sclerosis Drug Consumption Value (2019-2030) & (USD Million)

Figure 29. Asia-Pacific Systemic Sclerosis Drug Consumption Value (2019-2030) & (USD Million)

Figure 30. South America Systemic Sclerosis Drug Consumption Value (2019-2030) & (USD Million)

Figure 31. Middle East & Africa Systemic Sclerosis Drug Consumption Value (2019-2030) & (USD Million)

Figure 32. Global Systemic Sclerosis Drug Sales Quantity Market Share by Type (2019-2030)

Figure 33. Global Systemic Sclerosis Drug Consumption Value Market Share by Type (2019-2030)

Figure 34. Global Systemic Sclerosis Drug Average Price by Type (2019-2030) & (USD/Pcs)

Figure 35. Global Systemic Sclerosis Drug Sales Quantity Market Share by Application (2019-2030)

Figure 36. Global Systemic Sclerosis Drug Consumption Value Market Share by Application (2019-2030)

Figure 37. Global Systemic Sclerosis Drug Average Price by Application (2019-2030) & (USD/Pcs)

Figure 38. North America Systemic Sclerosis Drug Sales Quantity Market Share by Type (2019-2030)

Figure 39. North America Systemic Sclerosis Drug Sales Quantity Market Share by Application (2019-2030)

Figure 40. North America Systemic Sclerosis Drug Sales Quantity Market Share by Country (2019-2030)

Figure 41. North America Systemic Sclerosis Drug Consumption Value Market Share by Country (2019-2030)

Figure 42. United States Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 43. Canada Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 44. Mexico Systemic Sclerosis Drug Consumption Value and Growth Rate

(2019-2030) & (USD Million)

Figure 45. Europe Systemic Sclerosis Drug Sales Quantity Market Share by Type (2019-2030)

Figure 46. Europe Systemic Sclerosis Drug Sales Quantity Market Share by Application (2019-2030)

Figure 47. Europe Systemic Sclerosis Drug Sales Quantity Market Share by Country (2019-2030)

Figure 48. Europe Systemic Sclerosis Drug Consumption Value Market Share by Country (2019-2030)

Figure 49. Germany Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 50. France Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 51. United Kingdom Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 52. Russia Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 53. Italy Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 54. Asia-Pacific Systemic Sclerosis Drug Sales Quantity Market Share by Type (2019-2030)

Figure 55. Asia-Pacific Systemic Sclerosis Drug Sales Quantity Market Share by Application (2019-2030)

Figure 56. Asia-Pacific Systemic Sclerosis Drug Sales Quantity Market Share by Region (2019-2030)

Figure 57. Asia-Pacific Systemic Sclerosis Drug Consumption Value Market Share by Region (2019-2030)

Figure 58. China Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 59. Japan Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 60. Korea Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 61. India Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 62. Southeast Asia Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 63. Australia Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)



Figure 64. South America Systemic Sclerosis Drug Sales Quantity Market Share by Type (2019-2030)

Figure 65. South America Systemic Sclerosis Drug Sales Quantity Market Share by Application (2019-2030)

Figure 66. South America Systemic Sclerosis Drug Sales Quantity Market Share by Country (2019-2030)

Figure 67. South America Systemic Sclerosis Drug Consumption Value Market Share by Country (2019-2030)

Figure 68. Brazil Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 69. Argentina Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 70. Middle East & Africa Systemic Sclerosis Drug Sales Quantity Market Share by Type (2019-2030)

Figure 71. Middle East & Africa Systemic Sclerosis Drug Sales Quantity Market Share by Application (2019-2030)

Figure 72. Middle East & Africa Systemic Sclerosis Drug Sales Quantity Market Share by Region (2019-2030)

Figure 73. Middle East & Africa Systemic Sclerosis Drug Consumption Value Market Share by Region (2019-2030)

Figure 74. Turkey Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 75. Egypt Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 76. Saudi Arabia Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 77. South Africa Systemic Sclerosis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 78. Systemic Sclerosis Drug Market Drivers

Figure 79. Systemic Sclerosis Drug Market Restraints

Figure 80. Systemic Sclerosis Drug Market Trends

Figure 81. Porters Five Forces Analysis

Figure 82. Manufacturing Cost Structure Analysis of Systemic Sclerosis Drug in 2023

Figure 83. Manufacturing Process Analysis of Systemic Sclerosis Drug

Figure 84. Systemic Sclerosis Drug Industrial Chain

Figure 85. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 86. Direct Channel Pros & Cons

Figure 87. Indirect Channel Pros & Cons

Figure 88. Methodology

Figure 89. Research Process and Data Source

## I would like to order

Product name: Global Systemic Sclerosis Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/GB7A656D03A1EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB7A656D03A1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

